Boehringer Ingelheim Vetmedica Gmbh

Other

Dianna M Murphy Jordan

Arun V Iyer

Eric Martin Vaughn

Michael B Roof

Joseph Gilbert Victoria

Brian Thomas Martinson

Abby Rae Patterson

Christine Margaret Muehlenthaler

Axel Neubauer

Luis Alejandro Hernandez

Callie Ann Visek

The present invention relates to an immunogenic composition comprising: a) one or more antigen ofand one or more antigens ofand b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting ofandand b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting ofandin a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.

Immunogenic composition comprising mycoplasma antigens

The present invention relates to immunogenic compositions, wherein the immunogenic compositions include a recombinant spike antigen porcine epidemic diarrhea virus (PEDV). The immunogenic compositions commonly include an oil-in-water emulsion as an adjuvant. Methods for producing the immunogenic compositions and the recombinant PEDV spike antigen are also provided.

Porcine epidemic diarrhea virus vaccine

The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.

Method of making a mycoplasma vaccine

The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.

The present invention relates to an immunogenic composition comprising: a) one or more antigen ofand one or more antigens of; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or moreantigens ofbacteria selected from the group consisting ofand; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of abacteria selected from the group consisting ofandin a serum-reduced, eukaryotic cell system; b) obtaining an antigen of suchbacteria; and c) addition of a pharmaceutically acceptable carrier.

The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.

Porcine parvovirus 5A, methods of use and vaccine

The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.

Porcine parvovirus 5B, methods of use and vaccine

The present invention relates to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) mutant strains having increased stability; compositions containing the strains or antigens derived therefrom; vaccines containing the strains, including killed, attenuated or subunit vaccines; nucleic acids encoding PRRSV polypeptides, polypeptides encoded by the nucleic acids, including antigenic fragments thereof; antibodies which specifically bind to said polypeptides, and methods making and using thereof.

Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use

The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis ofinfections in a subject comprising the cultivation ofbacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of thebacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.

Growing community of inventors

Ames, IA, United States of America

Dianna M Murphy Jordan